Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD

Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD

Edward M Kerwin,1 Robert Tosiello,2 Barry Price,2 Shahin Sanjar,2 Thomas Goodin2 1Clinical Research Institute of Southern Oregon, Inc., Medford, OR, USA; 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA Background: Phase III studies demonstrated efficacy and safety of nebulized glycopyrrolate...

Full description

Bibliographic Details
Main Authors: Kerwin EM, Tosiello R, Price B, Sanjar S, Goodin T
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:International Journal of COPD
Subjects:
COPD
nebulized glycopyrrolate
eFlow® CS
LAMA
background LABA
Online Access:https://www.dovepress.com/effect-of-background-long-acting-beta2-agonist-therapy-on-the-efficacy-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/effect-of-background-long-acting-beta2-agonist-therapy-on-the-efficacy-peer-reviewed-article-COPD

Similar Items